## Keerti Jain

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4369154/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nanoemulgel: a promising novel formulation for treatment of skin ailments. Polymer Bulletin, 2022, 79, 4441-4465.	3.3	20
2	Emerging trends and promises of nanoemulsions inÂtherapeutics ofÂinfectious diseases. Nanomedicine, 2022, 17, 793-812.	3.3	11
3	Nanoemulsions as effective carriers for targeting brain tumors. , 2022, , 347-363.		7
4	Emerging concerns of infectious diseases and drug delivery challenges. , 2022, , 1-23.		4
5	Dendrimers and its theranostic applications in infectious diseases. , 2022, , 199-228.		3
6	3D Printing in Development of Nanomedicines. Nanomaterials, 2021, 11, 420.	4.1	35
7	Advances in dendrimer-mediated targeted drug delivery to the brain. Journal of Nanoparticle Research, 2021, 23, 1.	1.9	33
8	Nanotechnology in Wastewater Management: A New Paradigm Towards Wastewater Treatment. Molecules, 2021, 26, 1797.	3.8	158
9	Impact of binary/ternary solid dispersion utilizing poloxamer 188 and TPGS to improve pharmaceutical attributes of bedaquiline fumarate. Journal of Drug Delivery Science and Technology, 2021, 62, 102349.	3.0	10
10	Types of dendrimers. , 2021, , 95-123.		8
11	Receptor-Mediated Targeted Delivery of Surface-ModifiedNanomedicine in Breast Cancer: Recent Update and Challenges. Pharmaceutics, 2021, 13, 2039.	4.5	14
12	IPN Dendrimers in Drug Delivery. , 2020, , 143-181.		5
13	PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discovery Today, 2019, 24, 2181-2191.	6.4	170
14	Topical Nano-emulgel for Skin Disorders: Formulation Approach and Characterization. Recent Patents on Anti-infective Drug Discovery, 2019, 14, 36-48.	0.8	44
15	Nanocrystalization: An Emerging Technology to Enhance the Bioavailability of Poorly Soluble Drugs. Pharmaceutical Nanotechnology, 2019, 7, 259-278.	1.5	39
16	3D Printing in Personalized Drug Delivery. Current Pharmaceutical Design, 2019, 24, 5062-5071.	1.9	59
17	Dendrimer nanohybrid carrier systems: an expanding horizon for targeted drug and gene delivery. Drug Discovery Today, 2018, 23, 300-314.	6.4	100
18	Molecular targets and pathways for the treatment of visceral leishmaniasis. Drug Discovery Today, 2018. 23. 161-170.	6.4	38

Keerti Jain

#	Article	IF	CITATIONS
19	A Comparative Study of Consumption Behavior of Pharmaceutical Drugs. Communications in Computer and Information Science, 2018, , 27-33.	0.5	2
20	Nanohybrids of Dendrimers and Carbon Nanotubes: A Benefaction or Forfeit in Drug Delivery?. Nanoscience and Nanotechnology - Asia, 2018, 9, 21-29.	0.7	15
21	Development and characterization of surface engineered PPI dendrimers for targeted drug delivery. Artificial Cells, Nanomedicine and Biotechnology, 2017, 45, 414-425.	2.8	52
22	Dendrimers. , 2017, , 169-220.		15
23	Pharmaceutical and biomedical applications of quantum dots. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 1-11.	2.8	43
24	Multifunctional carbon nanotubes in cancer therapy and imaging. , 2016, , 421-453.		3
25	A review on comparative study of PPI and PAMAM dendrimers. Journal of Nanoparticle Research, 2016, 18, 1.	1.9	112
26	Dendrimers in anticancer drug delivery: mechanism of interaction of drug and dendrimers. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 1626-1634.	2.8	94
27	Targeted anticancer drug delivery through anthracycline antibiotic bearing functionalized quantum dots. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 1774-1782.	2.8	30
28	Biomedical Applications of Carbon Nanotubes: A Critical Review. Current Drug Delivery, 2016, 13, 796-817.	1.6	78
29	Characterization and evaluation of amphotericin B loaded MDP conjugated poly(propylene imine) dendrimers. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 705-713.	3.3	85
30	Pharmaceutical and biomedical applications of surface engineered carbon nanotubes. Drug Discovery Today, 2015, 20, 750-759.	6.4	84
31	Surface-Engineered Dendrimeric Nanoconjugates for Macrophage-Targeted Delivery of Amphotericin B: Formulation Development and <i>In Vitro</i> and <i>In Vivo</i> Evaluation. Antimicrobial Agents and Chemotherapy, 2015, 59, 2479-2487.	3.2	76
32	Vaccines for visceral leishmaniasis: A review. Journal of Immunological Methods, 2015, 422, 1-12.	1.4	128
33	Controlled delivery of Gemcitabine Hydrochloride using mannosylated poly(propyleneimine) dendrimers. Journal of Nanoparticle Research, 2015, 17, 1.	1.9	24
34	Dendrimer Internalization: A Systematic Review. Journal of Colloid Science and Biotechnology, 2015, 4, 99-109.	0.2	4
35	Nanotechnology in Drug Delivery: Safety and Toxicity Issues. Current Pharmaceutical Design, 2015, 21, 4252-4261.	1.9	34
36	Dendrimer as nanocarrier for drug delivery. Progress in Polymer Science, 2014, 39, 268-307.	24.7	886

Keerti Jain

#	Article	IF	CITATIONS
37	Potentials and emerging trends in nanopharmacology. Current Opinion in Pharmacology, 2014, 15, 97-106.	3.5	59
38	Dendronized nanoconjugates of lysine and folate for treatment of cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 500-509.	4.3	77
39	Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: In vitro and in vivo assessment. International Journal of Pharmaceutics, 2013, 456, 31-40.	5.2	213
40	Novel therapeutic strategies for treatment of visceral leishmaniasis. Drug Discovery Today, 2013, 18, 1272-1281.	6.4	73
41	Lipoproteins tethered dendrimeric nanoconstructs for effective targeting to cancer cells. Journal of Nanoparticle Research, 2013, 15, 1.	1.9	26
42	Low density lipoproteins mediated nanoplatforms for cancer targeting. Journal of Nanoparticle Research, 2013, 15, 1.	1.9	33
43	A review of glycosylated carriers for drug delivery. Biomaterials, 2012, 33, 4166-4186.	11.4	232
44	Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 295-304.	3.3	152
45	Dendrimer toxicity: Let's meet the challenge. International Journal of Pharmaceutics, 2010, 394, 122-142.	5.2	627